Phase 3 Recruiting NIH
This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarc…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06422806
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Cancer Care and Hematology-Fort Collins — Fort Collins, Colorado
- UCHealth Greeley Hospital — Greeley, Colorado
- Medical Center of the Rockies — Loveland, Colorado
Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver, Colorado
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver, Colorado
Phase 3 Recruiting Network
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…
Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center — Denver, Colorado
Phase 3 Recruiting Network
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyos…
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
NCT ID: NCT04031677
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
Phase 3 Recruiting Industry
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
Sponsor: Polaris Group
NCT ID: NCT05712694
Sites in Colorado: - University of Colorado Cancer Center/ CU Anschutz Medical Campus — Aurora, Colorado
Phase 3 Recruiting Industry
The primary objective of this phase III study is to evaluate whether the combination of lurbinectedin plus doxorubicin given as first line treatment for metastatic leiomyosarcoma (LMS) prolongs the progression-free survival (PFS) by Indepe…
Sponsor: PharmaMar
NCT ID: NCT06088290
Sites in Colorado: - University of Colorado Hospital - Anschutz Medical Campus — Aurora, Colorado
Phase 3 Recruiting Industry
THIS STUDY IS CURRENTLY RECRUITING PATIENTS WITH ALVEOLAR SOFT PART SARCOMA ONLY AND IS NO LONGER RECRUITING PATIENTS WITH SYNOVIAL SARCOMA OR LEIOMYOSARCOMA. This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride…
Sponsor: Advenchen Laboratories, LLC
NCT ID: NCT03016819
Sites in Colorado: - University of Colorado Denver — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Colorado: - Local Institution - 1003 — Aurora, Colorado
- Local Institution - 2103 — Aurora, Colorado
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Colorado: - University of Colorado Cancer Center — Aurora, Colorado
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT04094610
Sites in Colorado: - Children's Hospital Colorado - Anschutz Medical Campus — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Colorado: - Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016) — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in Colorado: - Grand Valley Oncology — Grand Junction, Colorado
Phase 1, Phase 2 Recruiting Academic/Other
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will …
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04901702
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado
Phase 2 Recruiting Academic/Other
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The pr…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05135975
Sites in Colorado: - Children's Hospital of Colorado — Aurora, Colorado
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
Sponsor: Adcendo ApS
NCT ID: NCT06797999
Sites in Colorado: - University of Colorado Denver — Aurora, Colorado
Phase 2 Recruiting Academic/Other
The overall goal of this Phase 2 study is to determine the efficacy of a lower dose weekly schedule of doxorubicin in patients with unresectable leiomyosarcomas aged 65-100 years old. While doxorubicin is the standard of care therapy for s…
Sponsor: University of Colorado, Denver
NCT ID: NCT07125183
Sites in Colorado: - University Of Colorado Hospital — Aurora, Colorado
Phase 1 Recruiting Industry
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding…
Sponsor: Kura Oncology, Inc.
NCT ID: NCT05735184
Sites in Colorado: - University of Colorado — Aurora, Colorado
- Colorado Blood Cancer Institute — Denver, Colorado
Phase 1 Recruiting Industry
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05245500
Sites in Colorado: - Sarah Cannon Research Institute (SCRI) - HealthONE Location — Denver, Colorado
- Rocky Mountain Cancer Centers, LLP - Oncology — Lone Tree, Colorado
Phase 1 Recruiting Industry
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT03715933
Sites in Colorado: - University of Colorado Hospital — Aurora, Colorado
Phase 1 Recruiting NIH
This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sarcoma that has spread from where it first started, to other places in the body (m…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05711615
Sites in Colorado: - UCHealth University of Colorado Hospital — Aurora, Colorado
Phase 1 Recruiting Industry
This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 w…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06884618
Sites in Colorado: - University of Colorado - Anschutz Medical Campus - PPDS — Aurora, Colorado
Phase 1 Recruiting Industry
This first-in-human (FIH) trial is designed to assess the safety, feasibility and preliminary efficacy of a single intravenous (IV) dose of SynKIR-310 administered to participants with relapsed/refractory B-NHL.
Sponsor: Verismo Therapeutics
NCT ID: NCT06544265
Sites in Colorado: - Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute — Denver, Colorado
Phase 1 Recruiting Academic/Other
The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory sarcomas.
Sponsor: Children's Hospital of Philadelphia
NCT ID: NCT06156410
Sites in Colorado: - Children's Hospital Colorado — Aurora, Colorado